Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Receives $48.00 Average Price Target from Brokerages
Sensei Biotherapeutics (NASDAQ:SNSE) received an average 12-month price target of $48.00 from seven brokerages, with one sell, two hold, and four buy ratings, MarketBeat reported. Citigroup set a $55 buy target; Loop Capital set $50. The stock opened at $14.15; last quarter EPS was ($131.45) vs ($0.62) consensus.
How this was made
The 30-second read
Why it matters
This article updates the Street’s stance (Hold average, one sell, multiple buys) and reports SEC-disclosed insider activity (Millennium Management buy; James Peyer sale). It also reiterates the last reported quarterly EPS miss (May 15).
Market read
Traders get a sentiment snapshot via updated analyst ratings/targets and a modest supportive signal from a disclosed insider buy, but no new fundamental catalyst.
What to watch
The most decision-relevant item would be new trial data, financing terms, or regulatory updates; none are provided here, so traders may overreact to targets/insider flows.
Background
Sensei Biotherapeutics is a clinical-stage biotech with lead programs SIS-100 (Siglec-15 antagonist) and SIS-101 (CD39 antibody).
Ticker impact
Article cites fresh analyst coverage with a $48 average 12-month price objective and details an insider buy by Millennium Management on Mar 27.
Likely limited, sentiment-driven reaction; any move should fade unless followed by new clinical/financing catalysts.
The piece is primarily an analyst-target recap plus disclosed insider transactions; it does not introduce new clinical/regulatory outcomes or fresh company guidance.
Market effects
For small-cap clinical-stage biotech, analyst target dispersion can influence risk appetite but does not change fundamental trial/regulatory timelines.
No clear regional spillover beyond US small-cap biotech sentiment.
No direct global linkage; story is company-specific coverage/insider activity.
Counterpoint
The average $48 target is far above the current ~$14 open, but the article’s own consensus is “Hold,” suggesting upside may be more narrative than catalyst-driven.
Key entities
- companySensei Biotherapeutics, Inc.
Clinical-stage biotech; subject of analyst coverage, price targets, and insider transactions in the article.
- insider/major shareholderMillennium Management LLC
Bought 15,321 shares at an average $26.61 per share on Mar 27 (SEC-disclosed).
- insider/major shareholderJames Peyer
Sold 25,000 shares at an average $20.02 per share on Jun 1 (SEC-disclosed).
